NimBio finalist in EIT Health Programme

NimBio is thrilled to announce its selection as a finalist in the EIT Health Open Innovation Programme for inflammatory bowel diseases (IBD), in partnership with Takeda and KU Leuven.

We are proud to share NimBio has been selected into the first cohort for the Open Innovation IBD Challenge to advance our promising technology for early detection of IBD flares and optimizing disease management.

Here at NimBio, we are dedicated to improving the quality of life for individuals affected by IBD. Our cutting-edge technology utilizes inflammatory biomarkers tracked effortlessly through non-invasive and continuous digital measurements, enabling proactive and remote disease management.